Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

Li, Yutao; Sharma, Amit; Schmidt-Wolf, Ingo G.H.

doi:10.1186/s12943-023-01926-4

Fig. 3

From: Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

Interaction of PD-1/PD-L1 between T cells and NSCLC cells. (A-B) The engagement of PD-1 in T cells and PD-1 ligands leads to the recruitment of SHP-1/2 (Src homology 2-containing tyrosine phosphatase 1/2) to the C-terminal of the ITSM. SHP-2 then dephosphorylates TCR-associated CD-3ζ and ZAP70, resulting in the inhibition of downstream signaling and T cell inactivation (A). In the presence of Anti-PD-1 mAb, T cells might be reactivated via PD-1/PD-L1 axis (B). (C-D) The effect of tumor cell-intrinsic PD-1 on NSCLC cells. PD-L1 expressed by NSCLC cells or other cells acts on PD-1⁺ tumor cells to mediate PD-1 signaling in tumor cells via ITIM and ITSM. The AKT and ERK1/2 pathways can suppress tumor growth by dampening AKT and ERK signaling (C). Anti-PD 1 mAb blocks PD-1/PD-L1-mediated tumor suppression, leading to hyperprogression in NSCLC cells (D)

Back to article page

Fig. 3

Molecular Cancer

Contact us